[HTML][HTML] Design and optimization of oestrogen receptor PROTACs based on 4-hydroxytamoxifen
G Loren, I Espuny, A Llorente, C Donoghue… - European Journal of …, 2022 - Elsevier
In the last four decades, treatment of oestrogen receptor positive (ER+) breast cancer (BCa),
has focused on targeting the estrogenic receptor signaling pathway. This signaling function …
has focused on targeting the estrogenic receptor signaling pathway. This signaling function …
[PDF][PDF] Design and optimization of oestrogen receptor PROTACs based on 4-hydroxytamoxifen
G Loren, I Espuny, A Llorente… - European Journal of …, 2022 - researchgate.net
In the last four decades, treatment of oestrogen receptor positive (ER+) breast cancer (BCa),
has focused on targeting the estrogenic receptor signaling pathway. This signaling function …
has focused on targeting the estrogenic receptor signaling pathway. This signaling function …
[PDF][PDF] Design and optimization of Oestrogen Receptor PROTACs based on 4-hydroxytamoxifen
G Loren, I Espuny, A Llorente, C Donoghue… - scholar.archive.org
In the last four decades, treatment of oestrogen receptor positive (ER+) breast cancer (BCa),
has focused on targeting the estrogenic receptor signaling pathway. This signaling function …
has focused on targeting the estrogenic receptor signaling pathway. This signaling function …
Design and optimization of oestrogen receptor PROTACs based on 4-hydroxytamoxifen
G Loren, I Espuny, A Llorente Lope… - … 2022, vol. 243, p. 1-14, 2022 - diposit.ub.edu
In the last four decades, treatment of oestrogen receptor positive (ER+) breast cancer (BCa),
has focused on targeting the estrogenic receptor signaling pathway. This signaling function …
has focused on targeting the estrogenic receptor signaling pathway. This signaling function …
Design and optimization of Oestrogen Receptor PROTACs based on 4-hydroxytamoxifen
G Loren, I Espuny, A Llorente, C Donoghue… - 2022 - chemrxiv.org
In the last four decades, treatment of oestrogen receptor positive (ER+) breast cancer (BCa),
has focused on targeting the estrogenic receptor signaling pathway. This signaling function …
has focused on targeting the estrogenic receptor signaling pathway. This signaling function …
Design and optimization of oestrogen receptor PROTACs based on 4-hydroxytamoxifen
G Loren, I Espuny, A Llorente… - European journal …, 2022 - pubmed.ncbi.nlm.nih.gov
In the last four decades, treatment of oestrogen receptor positive (ER+) breast cancer (BCa),
has focused on targeting the estrogenic receptor signaling pathway. This signaling function …
has focused on targeting the estrogenic receptor signaling pathway. This signaling function …